About US
Contact us
-
Gilead’s Descovy secures FDA approval for HIV preventionGilead Sciences has secured the US Food and Drug Administration (FDA) approval for Descovy in pre-exposure prophylaxis (PrEP) to mitigate the risk of sexually acquired HIV-1 infection. The drug is in2019/9/26
-
UK’s NICE rejects Roche’s Tecentriq for triple negative breast cancerThe UK’s National Institute for Health and Care Excellence (NICE) has rejected the first targeted immunotherapy treatment for people with triple negative breast cancer for use on the NHS. The cost wa2019/9/25
-
Keytruda approved in China as a monotherapy for NSCLCMerck has announced that Keytruda has been approved by the Chinese National Medical Products Administration (NMPA) as a monotherapy for first-line treatment of local advanced or metastatic non-small2019/9/25
-
Servier acquires non-Hodgkin lymphoma drug from CTI BioPharmaFrench pharmaceutical company Servier has purchased Pixuvri medicine, indicated for the treatment of non-Hodgkin B-cell lymphoma, from US-based CTI BioPharma. Financial details of the transaction are2019/9/24
-
Novartis teams up with Microsoft for AI drug developmentNovartis has allied with Microsoft to leverage the latter’s artificial intelligence (AI) technology for the discovery, development and commercialisation of medicines. Under the multi-year collaborati2019/9/24
-
J&J resolves opioid lawsuits in two Ohio counties for $20.4mUS pharma giant Johnson & Johnson (J&J) has announced the resolution and settlement of all opioid-based lawsuits with two Ohio counties, Cuyahoga and Summit, for $10m. This means the company2019/9/23
-
Roche’s Tecentriq performs well in untreated bladder cancerRoche has announced positive results of Tecentriq (atezolizumab) combined with platinum-based chemotherapy in a Phase III study of patients with previously untreated advanced or metastatic urothelial2019/9/23
-
Sobi to purchase Dova Pharmaceuticals in $915m dealSwedish Orphan Biovitrum AB (Sobi) has agreed to acquire US-based Dova Pharmaceuticals in a transaction valued up to $915m. Dova Pharmaceuticals was established in 2016 to commercialise Doptelet, a s2019/9/20
-
Cheplapharm to acquire Losec’s global commercial rights for $243mGerman pharmaceutical company Cheplapharm Arzneimittel has signed an agreement to purchase global commercial rights for Losec (omeprazole) from AstraZeneca for $243m. Under the agreement, Cheplapharm2019/9/20
-
Moberg Pharma signs deal with Taisho for MOB-015 developmentSwedish company Moberg Pharma has signed an agreement with Taisho Pharmaceutical towards the development, registration and commercialisation of MOB-015 in Japan. MOB-015 is a topical treatment of ony2019/9/19